Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MME | P08473 | 2/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGAV | P06756 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NMBR | P28336 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2236885 | 1.00 | SMN1; SMN2 (0.49) | SMN1; SMN2MMEITGB3ITGAVALDH1A1 | |
| SCHEMBL27693754 | 0.84 | SMN1; SMN2 (0.39) | SMN1; SMN2MMEITGB3ITGAVLMNA | |
| SCHEMBL12993100 | 0.84 | CAPN1 (0.40) | MMEALDH1A1FOLH1CTSK | |
| SCHEMBL2234720 | 0.84 | MME (0.53) | SMN1; SMN2MMEITGB3ITGAVALDH1A1 | |
| SCHEMBL2234718 | 0.84 | MME (0.53) | SMN1; SMN2MMEITGB3ITGAVALDH1A1 | |
| SCHEMBL18190834 | 0.84 | ALDH1A1 (0.58) | SMN1; SMN2MMEALDH1A1FOLH1CTSK | |
| SCHEMBL754070 | 0.83 | TGFBR1 (0.42) | SMN1; SMN2MMEALDH1A1FOLH1LMNA | |
| SCHEMBL1293468 | 0.83 | TGFBR1 (0.42) | SMN1; SMN2MMEALDH1A1FOLH1LMNA | |
| SCHEMBL8088657 | 0.82 | SMN1; SMN2 (0.49) | SMN1; SMN2MMEITGB3ITGAVALDH1A1 | |
| SCHEMBL6763914 | 0.82 | SMN1; SMN2 (0.53) | SMN1; SMN2MMEITGB3ITGAVALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130041180-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2013-02-14 | — | — | US | claimed |
| US-8907132-B2 | Process for preparing (R)-2-acetamido-N-benzyl-3-methoxy-propionamide | MSN LABORATORIES PRIVATE LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| US-8907132-B2 | Process for preparing (R)-2-acetamido-N-benzyl-3-methoxy-propionamide | MSN LABORATORIES PRIVATE LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| US-20130041180-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2013-02-14 | — | — | US | disclosed |
| US-20130041180-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2013-02-14 | — | — | US | disclosed |
| EP-2534127-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | MSN Laboratories Limited (IN) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011099033-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | MSN LABORATORIES LIMITED (IN) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011099033-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | MSN LABORATORIES LIMITED (IN) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130041180-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | AMY1A, PTMA, NAAA | SMN1; SMN2 266/4885MME 306/4885ITGB3 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.